![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NSD3 |
Gene summary for NSD3 |
![]() |
Gene information | Species | Human | Gene symbol | NSD3 | Gene ID | 54904 |
Gene name | nuclear receptor binding SET domain protein 3 | |
Gene Alias | KMT3F | |
Cytomap | 8p11.23 | |
Gene Type | protein-coding | GO ID | GO:0000414 | UniProtAcc | Q9BZ95 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54904 | NSD3 | GSM4909281 | Human | Breast | IDC | 3.80e-09 | 3.38e-01 | 0.21 |
54904 | NSD3 | GSM4909282 | Human | Breast | IDC | 1.33e-10 | 4.14e-01 | -0.0288 |
54904 | NSD3 | GSM4909286 | Human | Breast | IDC | 3.09e-15 | 3.07e-01 | 0.1081 |
54904 | NSD3 | GSM4909297 | Human | Breast | IDC | 2.95e-22 | 6.63e-01 | 0.1517 |
54904 | NSD3 | GSM4909298 | Human | Breast | IDC | 2.56e-75 | 1.09e+00 | 0.1551 |
54904 | NSD3 | GSM4909304 | Human | Breast | IDC | 3.27e-02 | 2.07e-01 | 0.1636 |
54904 | NSD3 | GSM4909305 | Human | Breast | IDC | 2.10e-03 | 3.02e-01 | 0.0436 |
54904 | NSD3 | GSM4909306 | Human | Breast | IDC | 7.40e-07 | 3.48e-01 | 0.1564 |
54904 | NSD3 | GSM4909307 | Human | Breast | IDC | 1.36e-02 | 2.51e-01 | 0.1569 |
54904 | NSD3 | GSM4909308 | Human | Breast | IDC | 3.24e-07 | 2.89e-01 | 0.158 |
54904 | NSD3 | GSM4909309 | Human | Breast | IDC | 2.15e-06 | 4.34e-01 | 0.0483 |
54904 | NSD3 | GSM4909311 | Human | Breast | IDC | 1.08e-04 | -1.70e-01 | 0.1534 |
54904 | NSD3 | GSM4909317 | Human | Breast | IDC | 1.47e-55 | 1.05e+00 | 0.1355 |
54904 | NSD3 | GSM4909318 | Human | Breast | IDC | 6.46e-19 | 1.08e+00 | 0.2031 |
54904 | NSD3 | GSM4909319 | Human | Breast | IDC | 2.18e-11 | -6.66e-02 | 0.1563 |
54904 | NSD3 | brca1 | Human | Breast | Precancer | 8.25e-07 | -2.20e-01 | -0.0338 |
54904 | NSD3 | brca2 | Human | Breast | Precancer | 8.30e-08 | -2.20e-01 | -0.024 |
54904 | NSD3 | brca3 | Human | Breast | Precancer | 3.84e-07 | -2.20e-01 | -0.0263 |
54904 | NSD3 | M1 | Human | Breast | IDC | 7.26e-22 | 6.92e-01 | 0.1577 |
54904 | NSD3 | NCCBC2 | Human | Breast | DCIS | 1.04e-13 | 9.10e-01 | 0.1554 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00104525 | Cervix | CC | histone H3-K36 methylation | 8/2311 | 15/18723 | 1.53e-04 | 1.85e-03 | 8 |
GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
GO:00349685 | Cervix | CC | histone lysine methylation | 27/2311 | 115/18723 | 6.61e-04 | 6.09e-03 | 27 |
GO:00310565 | Cervix | CC | regulation of histone modification | 33/2311 | 152/18723 | 7.97e-04 | 7.00e-03 | 33 |
GO:00165715 | Cervix | CC | histone methylation | 30/2311 | 141/18723 | 1.88e-03 | 1.39e-02 | 30 |
GO:00180224 | Cervix | CC | peptidyl-lysine methylation | 28/2311 | 131/18723 | 2.43e-03 | 1.71e-02 | 28 |
GO:00064795 | Cervix | CC | protein methylation | 36/2311 | 181/18723 | 2.46e-03 | 1.71e-02 | 36 |
GO:00082135 | Cervix | CC | protein alkylation | 36/2311 | 181/18723 | 2.46e-03 | 1.71e-02 | 36 |
GO:00182054 | Cervix | CC | peptidyl-lysine modification | 62/2311 | 376/18723 | 1.04e-02 | 4.97e-02 | 62 |
GO:0010452 | Colorectum | AD | histone H3-K36 methylation | 8/3918 | 15/18723 | 5.67e-03 | 3.64e-02 | 8 |
GO:0031056 | Colorectum | AD | regulation of histone modification | 45/3918 | 152/18723 | 7.05e-03 | 4.31e-02 | 45 |
GO:00310561 | Colorectum | SER | regulation of histone modification | 37/2897 | 152/18723 | 2.80e-03 | 2.50e-02 | 37 |
GO:0016570 | Colorectum | MSS | histone modification | 113/3467 | 463/18723 | 8.37e-04 | 8.68e-03 | 113 |
GO:00310562 | Colorectum | MSS | regulation of histone modification | 41/3467 | 152/18723 | 6.41e-03 | 4.27e-02 | 41 |
GO:00165701 | Colorectum | FAP | histone modification | 94/2622 | 463/18723 | 1.06e-04 | 1.76e-03 | 94 |
GO:00104521 | Colorectum | FAP | histone H3-K36 methylation | 8/2622 | 15/18723 | 3.75e-04 | 4.63e-03 | 8 |
GO:0006479 | Colorectum | FAP | protein methylation | 39/2622 | 181/18723 | 3.60e-03 | 2.58e-02 | 39 |
GO:0008213 | Colorectum | FAP | protein alkylation | 39/2622 | 181/18723 | 3.60e-03 | 2.58e-02 | 39 |
GO:0034968 | Colorectum | FAP | histone lysine methylation | 27/2622 | 115/18723 | 4.23e-03 | 2.90e-02 | 27 |
GO:0016571 | Colorectum | FAP | histone methylation | 31/2622 | 141/18723 | 6.47e-03 | 4.03e-02 | 31 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00310 | Colorectum | AD | Lysine degradation | 27/2092 | 63/8465 | 1.17e-03 | 7.75e-03 | 4.94e-03 | 27 |
hsa003101 | Colorectum | AD | Lysine degradation | 27/2092 | 63/8465 | 1.17e-03 | 7.75e-03 | 4.94e-03 | 27 |
hsa003102 | Colorectum | MSS | Lysine degradation | 24/1875 | 63/8465 | 2.94e-03 | 1.39e-02 | 8.50e-03 | 24 |
hsa003103 | Colorectum | MSS | Lysine degradation | 24/1875 | 63/8465 | 2.94e-03 | 1.39e-02 | 8.50e-03 | 24 |
hsa003104 | Colorectum | FAP | Lysine degradation | 23/1404 | 63/8465 | 1.04e-04 | 9.46e-04 | 5.76e-04 | 23 |
hsa003105 | Colorectum | FAP | Lysine degradation | 23/1404 | 63/8465 | 1.04e-04 | 9.46e-04 | 5.76e-04 | 23 |
hsa003106 | Colorectum | CRC | Lysine degradation | 18/1091 | 63/8465 | 7.21e-04 | 6.34e-03 | 4.30e-03 | 18 |
hsa003107 | Colorectum | CRC | Lysine degradation | 18/1091 | 63/8465 | 7.21e-04 | 6.34e-03 | 4.30e-03 | 18 |
hsa0031010 | Esophagus | ESCC | Lysine degradation | 41/4205 | 63/8465 | 9.63e-03 | 2.27e-02 | 1.16e-02 | 41 |
hsa0031013 | Esophagus | ESCC | Lysine degradation | 41/4205 | 63/8465 | 9.63e-03 | 2.27e-02 | 1.16e-02 | 41 |
hsa003108 | Liver | NAFLD | Lysine degradation | 21/1043 | 63/8465 | 1.09e-05 | 3.58e-04 | 2.89e-04 | 21 |
hsa0031011 | Liver | NAFLD | Lysine degradation | 21/1043 | 63/8465 | 1.09e-05 | 3.58e-04 | 2.89e-04 | 21 |
hsa0031021 | Liver | Cirrhotic | Lysine degradation | 29/2530 | 63/8465 | 4.81e-03 | 1.74e-02 | 1.07e-02 | 29 |
hsa0031031 | Liver | Cirrhotic | Lysine degradation | 29/2530 | 63/8465 | 4.81e-03 | 1.74e-02 | 1.07e-02 | 29 |
hsa0031041 | Liver | HCC | Lysine degradation | 47/4020 | 63/8465 | 1.02e-05 | 7.58e-05 | 4.22e-05 | 47 |
hsa0031051 | Liver | HCC | Lysine degradation | 47/4020 | 63/8465 | 1.02e-05 | 7.58e-05 | 4.22e-05 | 47 |
hsa003109 | Lung | IAC | Lysine degradation | 17/1053 | 63/8465 | 1.35e-03 | 8.63e-03 | 5.73e-03 | 17 |
hsa0031012 | Lung | IAC | Lysine degradation | 17/1053 | 63/8465 | 1.35e-03 | 8.63e-03 | 5.73e-03 | 17 |
hsa0031022 | Lung | AIS | Lysine degradation | 16/961 | 63/8465 | 1.41e-03 | 9.49e-03 | 6.07e-03 | 16 |
hsa0031032 | Lung | AIS | Lysine degradation | 16/961 | 63/8465 | 1.41e-03 | 9.49e-03 | 6.07e-03 | 16 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NSD3 | SNV | Missense_Mutation | c.592N>G | p.Lys198Glu | p.K198E | Q9BZ95 | protein_coding | tolerated(0.06) | benign(0.015) | TCGA-CG-4442-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
NSD3 | SNV | Missense_Mutation | rs780032475 | c.3814G>C | p.Glu1272Gln | p.E1272Q | Q9BZ95 | protein_coding | tolerated(0.1) | benign(0.057) | TCGA-D7-6822-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NSD3 | SNV | Missense_Mutation | c.4003A>G | p.Met1335Val | p.M1335V | Q9BZ95 | protein_coding | deleterious(0.05) | probably_damaging(0.914) | TCGA-HU-A4GN-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | mitomycin | PD | |
NSD3 | SNV | Missense_Mutation | c.325A>G | p.Thr109Ala | p.T109A | Q9BZ95 | protein_coding | tolerated_low_confidence(1) | benign(0.003) | TCGA-HU-A4GN-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | mitomycin | PD | |
NSD3 | SNV | Missense_Mutation | novel | c.1679N>T | p.Ser560Leu | p.S560L | Q9BZ95 | protein_coding | tolerated(0.13) | benign(0.036) | TCGA-KB-A93G-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NSD3 | SNV | Missense_Mutation | novel | c.2886G>C | p.Gln962His | p.Q962H | Q9BZ95 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-RD-A8N1-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
NSD3 | SNV | Missense_Mutation | novel | c.3178N>A | p.Ala1060Thr | p.A1060T | Q9BZ95 | protein_coding | tolerated(0.41) | benign(0.193) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
NSD3 | SNV | Missense_Mutation | novel | c.2803N>T | p.Pro935Ser | p.P935S | Q9BZ95 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-VQ-A91E-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | CR |
NSD3 | insertion | Frame_Shift_Ins | novel | c.1255dupA | p.Thr419AsnfsTer28 | p.T419Nfs*28 | Q9BZ95 | protein_coding | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
NSD3 | insertion | Frame_Shift_Ins | novel | c.3197dupA | p.Asn1066LysfsTer14 | p.N1066Kfs*14 | Q9BZ95 | protein_coding | TCGA-BR-4370-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |